Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer

NCT01092481 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01092481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01092481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Unknown status
Start date
January 26, 2010
Completion date
December 31, 2019
Enrollment
1,580 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer